DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER

19701 Fairchild

Irvine, CA 92612-2445 (949)608-2900 Fax:(949)608-4417

Industry Information: www.fda.gov/oc/industry

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED

DATE(S) OF INSPECTION

7/12/2021-7/23/2021

FEI NUMBER

3015134033

TO: Eghomware J. Igbinovia, Owner and Pharmacist-in-Charge

FIRM NAME
ACRX Specialty Pharmacy Inc

3200 Soaring Gulls Dr Ste 101

STREET ADDRESS

-

TYPE OF ESTABLISHMENT INSPECTED

Las Vegas, NV 89129-2198

CITY, STATE AND ZIP CODE

Producer of Sterile and Non Sterile Drug Products

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

OBSERVATION 1

The ISO 5 classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.

Specifically,

It was observed that the ISO 5 classified aseptic processing areas contained difficult to clean and visibly dirty surfaces and that Pharmacist-in-Charge (PIC) did not clean them before and after producing Glutathione (BUD MDV) 200 mg/ml Inject Soln, Lot #07122021@8 on 7/12/2021 for the following:

- A. The HEPA filter cover positioned above the work surface inside the ISO 5 LAFH contained brownish stains on its surface.
- B. The frames of the HEPA filter and its joints with the ISO 5 LAFH contained brownish stains.
- C. There was a gap between a stainless-steel bar pot rack with hooks used to hold sterile bags or devices and the holder at its joint with the ISO 5 LAFH on both sides, which was difficult to clean.
- D. The red IVA seals holder hung on a bar pot rack inside the ISO5 LAFH. The IVA seals must be removed in order to clean the holder thoroughly.
- E. Unknown stains were observed in a hard-to-reach area under a row of light bulbs of the LAFH and near the HEPA filter.

OBSERVATION 2

Non-microbial contamination was observed in your production area.

SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE

EMPLOYEE(S) NAME AND TITLE (Print or Type)

DATE ISSUED

Taichun Qin, Investigator

7/23/2021

		ALTH AND HUMAN SERVICE RUG ADMINISTRATION	s		
DISTRICT OFFICE	ADDRESS AND PHONE NUMBER		DATE(\$) OF INSPECTION		
19701 Fairchile			7/12/2021-7/23/2021		
Irvine, CA 92612-2445			FEI NUMBER		
(949)608-2900 Fax:(949)608-4417					
NAME AND TITLE O	ation: www.fda.gov/oc/industry FINDIVIDUAL TO WHOM REPORT IS ISSUED		3015134033		
	re J. Igbinovia, Owner and Pharmacist-in-Charge				
FIRM NAME		STREET ADDRESS			
ACRX Specialt	CRX Specialty Pharmacy Inc 3200 Soaring Gul		s Dr Ste 101		
		TYPE OF ESTABLISHMENT I	HMENT INSPECTED		
Las Vegas, NV	89129-2198	Producer of Sterile and Non Sterile Drug Products			
sterile product at the corner of Glutathione (IB. Unknown used to product. Unknown D. A small bate for sterile control of SERVATI Your firm product.	th-like material was present on the back ts and to weigh ingredients used to product of the working surface after the hood has BUD MDV) 200 mg/ml Inject Soln, Lot stains were widely distributed on the integer non-sterile products. Trust-like stains were observed on a metal all of cotton-like substance and unknown inpounding in the ISO 7 cleanroom. HON 3 adduced drug products with materials that contamination that may be objectionable	been cleaned for weight #07122021@8 on 7/12/ erior surface of the front wheel of the ISO 5 LA brownish dirt stuck to a shad not been verified to	so, unknown powdering ingredients use /2021. t window of a (b) (4) FH located in the Is a cart used to store was a cart used to store was assure that they die	hood ((b) (4)) No 7 cleanroom. Various materials	
You used Glu Ml Inject Solo supplement fr Mg/Ml Inject Glutathione (I Rx(b) (6), R: Glutathione (I	n. For example, you purchased Glutathio from (b) (4) on 11/18/2020 and used Soln, Lot # 05102021@12 on 5/10/2021 BUD MDV) 200 Mg/MI Inject Soln for 9x(b) (6), Rx(b) (6), Rx(b) (6), Rx(b) (6), Rx(b) (6), dietary supplementation of the supplementation of	d this ingredient to prod. During the period of A prescription orders: R and Rx(b) (6); however the did not contribute which is 183 days after	, lot # (b) (4) luce Glutathione (B April to June 2021, x (b) (6) Rx(b) (6) vever, you have not to endotoxin contar the compounding de	, dietary UD MDV) 200 you produced), Rx(b) (6) verified that nination for every ate.	
SEE	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE	(Print or Type)	DATE ISSUED	
REVERSE OF THIS PAGE	CG	Taichun Qin, Investigator		7/23/2021	

	ALTH AND HUMAN SERVICES RUG ADMINISTRATION
DISTRICT OFFICE ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
19701 Fairchild	7/12/2021-7/23/2021
Irvine, CA 92612-2445	The state of the s
(949)608-2900 Fax:(949)608-4417	FEI NUMBER
Industry Information: www.fda.gov/oc/industry	3015134033
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED	<u> </u>
TO: Eghomware J. Igbinovia, Owner and Pharmacist-in-Charge	
FIRM NAME	STREET ADDRESS
ACRX Specialty Pharmacy Inc	3200 Soaring Gulls Dr Ste 101
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED
Las Vegas, NV 89129-2198	Producer of Sterile and Non Sterile Drug Products
Dynamic smoke studies are not representative of produ	uction.
Specifically,	
approximately a 45-degree angle to draw(b) (4) conducted 3/1/2021 showed a sterile bag hung on the hOBSERVATION 5 Personnel conducted aseptic manipulations and placed of first pass air around an open unit, either before or af	the immediately after PIC released the bag, which he held at from a port of the bag, but the video of smoke study mook was static. I equipment/supplies in an area that blocked the movement
Specifically,	
It was observed that a sterile bag containing (b) (4) swung back and forth for over a minute every time after port of the bag to dissolve bulk drug substances or othe (BUD MDV) 200 mg/ml Inject Soln, Lot #07122021@ opened sterile wipes, and syringes with exposed needled into a sterile vial approximately a foot apart for	er ingredients during aseptic processing of Glutathione 28 on 7/12/2021. Your sterile vial sealed with stopper, es were placed under or near the bag. Also, you(b) (4)
OBSERVATION 6	
Materials or supplies were not disinfected prior to ente	ering the aseptic processing areas.
Specifically,	
inside the non-sterile (b) (4) hood (b) (4)). It	ng boat used to produce a sterile drug product was weighed was observed that PIC used a (b) (4) sterile wipe to hold rking surface of the ISO5 LAFH without wiping the entire
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or Type) DATE ISSUED

SEE REVERSE OF THIS PAGE

Taichun Qin, Investigator

7/23/2021

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

TO: Eghomware J. Igbinovia, Owner and Pharmacist-in-Charge

FIRM NAME	STREET ADDRESS
ACRX Specialty Pharmacy Inc	3200 Soaring Gulls Dr Ste 101
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED
Las Vegas, NV 89129-2198	Producer of Sterile and Non Sterile Drug Products

OBSERVATION 7

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically,

Prior to donning gowning apparel, PIC washed his hands and forearms in a sink in the ISO 7 anteroom and then walked to a cart in the room to get wipes to dry his hands and forearms; however, it was observed water was dripping onto the ground from his hands and forearms. The shoe cover that touched the wet spillage had direct contact with the sterile gowning apparel while donning it or it can be brought into the ISO 7 cleanroom.

EMPLOYEE(S) SIGNATURE

EMPLOYEE(S) NAME AND TITLE (Print or Type)

DATE ISSUED

Taichun Qin, Investigator

7/23/2021

REVERSE OF THIS The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgement, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."